Effexor
(venlafaxine)ApprovedSmall molecule
Venlafaxine is used to treat depression, anxiety disorders, and panic disorder by helping to balance chemicals in the brain that affect mood and emotions.[2] Effexor is currently approved and in use across 31 indications[4].[1]
Effexor is one of 772 small molecule programs targeting Dyspepsia. It is currently in Approved.
31
Indications
111
Total Trials
8
Active Trials
771
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 30 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Effexor
WWyeth-Lederle Vaccines
Approved
Halaven
EisaiPreclinical
Megace
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Avastin
RochePreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Depression8 trials
Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression
Completed·—··NCT03126188·105 enrolled
Show 5 more trials
Major Depressive Disorder8 trials
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 4·NCT02051413·67 enrolled
Show 5 more trials
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Recruiting·—·Phase 3·NCT05603104·1,254 enrolled
Treatment Resistant Depression8 trials
Major Depression6 trials
Antidepressant Therapy for Bipolar II Major Depression
Completed·—·Phase 4·NCT00641927·90 enrolled
Show 3 more trials
The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)
Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 4·NCT06131268·30 enrolled
Hot flashes4 trials
59 more indications
Antidepressants3 trials
Obstructive Sleep Apnea3 trials
Treatment3 trials
Migraine2 trials
Acupuncture for Prophylaxis of Vestibular Migraine
Unknown status·—·N/A·NCT04664088·72 enrolled
Mood Disorder2 trials
Head and Neck Cancer2 trials
Generalized Anxiety Disorder2 trials
Electroencephalography2 trials
Efficacy2 trials
MPR2 trials
Fasting Conditions2 trials
Medication2 trials
Prostate Cancer2 trials
First-line Treatment1 trial
Dementia1 trial
Prostate Adenocarcinoma1 trial
Prevention1 trial
Peripheral Neuropathy1 trial
Laparoscopic Cholecystectomy1 trial
Randomized1 trial
Cardiac Repolarization1 trial
A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT02637193·54 enrolled
Complete Response1 trial
Social Anxiety Disorder1 trial
Tics1 trial
Total Knee Replacement1 trial
Pain1 trial
Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder
Recruiting·—·Phase 4·NCT06803485·84 enrolled
Infants1 trial
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Recruiting·—··NCT03511118·1,600 enrolled
Cohort Study1 trial
Randomised Controlled Trial1 trial
Sleep Disorder1 trial
Therapeutic Drug Monitoring (TDM)1 trial
Acute Kidney Injury1 trial
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02320240·3,255,526 enrolled
Osteoarthritis1 trial
Anxiety1 trial
Psychosocial and Medication Treatment for Anxiety in Alcoholism
Completed·—·Phase 2/3·NCT00248612·162 enrolled
Postmenopausal Women1 trial
Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
Completed·—·Phase 4·NCT01824433·189 enrolled
Safety and Efficacy1 trial
Neuropathy1 trial
Relapsing-Remitting Multiple Sclerosis1 trial
Fed1 trial
Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions
Completed·—·Phase 1·NCT01512459·33 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 28, 1993
EFFEXOR
NDA NDA020151
Oct 20, 1997
EFFEXOR XR
NDA NDA020699
May 20, 2008
VENLAFAXINE HYDROCHLORIDE
NDA NDA022104
Jun 29, 2022
VENLAFAXINE BESYLATE
NDA NDA215429
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Effexor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for venlafaxine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Norepinephrine Transporter Inhibitor; Serotonin Transporter Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWyeth-Lederle Vaccines
Patent Landscape[6]
Patent Cliff
May 16, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7776358May 16, 2028